Migraine

>

The NeurologyLive® Migraine Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with migraine disorders.

Latest News

Klaus Werner, MD, PhD (Credit: Duke University)
FDA Approves Expanded Age Indication for Nerivio Migraine Device in Pediatric Patients

November 14th 2024

Nerivio, a nondrug option for acute migraine attacks and prevention of migraine with or without aura, has been FDA-approved for several years in adolescents aged 12 and older as well as adults.

Ryoichi Nagata, MD, PhD, FFPM (Credit: Satsuma Pharmaceuticals)
Satsuma Resubmits NDA Over STS101 Nasal Powder for Acute Migraine Treatment

November 5th 2024

Aishwarya Taneja, MD, FAAP (Credit: Ampla Health)
College Checklist for People Living With Migraine

October 2nd 2024

FDA Accepts Resubmitted New Drug Application for Migraine Treatment AXS-07
FDA Accepts Resubmitted New Drug Application for Migraine Treatment AXS-07

September 4th 2024

NeurologyLive® Brain Games: September 1, 2024
NeurologyLive® Brain Games: September 1, 2024

September 1st 2024

More News

NeuroVoices: Stephanie J. Nahas, MD, on Migraine Treatment Gaps and Optimization

NeuroVoices: Stephanie J. Nahas, MD, on Migraine Treatment Gaps and Optimization

Marco Meglio
May 19th 2021
Article

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed treatment optimization for patients with migraine and raising overall awareness for preventive treatments.

Jason Sico, MD, MHS, FAHA, FAAN

Veterans Affairs Investigates gammaCore for Treatment of Post-Traumatic Headache

Victoria Johnson
May 17th 2021
Article

The study will be based in West Haven, Connecticut, and enroll up to 100 veterans with the headache disorder.

Atogepant’s Impact on Migraine Reductions and Patient-Reported Outcomes

Atogepant’s Impact on Migraine Reductions and Patient-Reported Outcomes

Marco Meglio
May 15th 2021
Article

Lawrence Severt, MD, PhD, discussed the results from the phase 3 ADVANCE trial of atogepant, and its effect on a number of patient-reported outcomes.

Advantages of Atogepant in Ever-Growing CGRP Market: Lawrence Severt, MD, PhD

Advantages of Atogepant in Ever-Growing CGRP Market: Lawrence Severt, MD, PhD

Lawrence Severt, MD, PhD
May 4th 2021
Video

The director at AbbVie highlighted where atogepant stands among the increasing treatment landscape of anti-calcitonin gene-related peptide options within the migraine treatment landscape.

Atogepant’s Impact on Patient-Reported Outcomes: Lawrence Severt, MD, PhD

Atogepant’s Impact on Patient-Reported Outcomes: Lawrence Severt, MD, PhD

Marco Meglio
April 28th 2021
Video

The director at AbbVie discussed a subgroup analysis of the phase 3 ADVANCE study of atogepant in patients with migraine and its benefit on patient-reported outcome measures.

<12
© 2024 MJH Life Sciences

All rights reserved.